Advanced Therapies Integrates 2022 Track 1
How do you secure VC investment? This track focuses on how to develop and present your advanced therapy innovation to secure investment.
Welcome and opening remarks
Viable cells to viable sells
How do you develop an investible opportunity that is commercially viable?
Mike Lyne | Translational Research Management Lead | NIHR Biomedical Research Centre
Joe Healey | Chief Executive Officer and Co-Founder | NanoSyrinx
Jason Mellad | Chief Executive Officer | Start Codon
Stefanos Theoharis | Independent Expert | Former Bone Therapeutics SA
Mustafa Munye | Director of R&D Operations | Complement Therapeutics
Catriona Crombie | Associate Director: Technology Transfer and Philanthropic Fund Manager | LifeArc
Pitch perfect: advancing therapies
How to present an investible opportunity, focusing on pitching, partnering and funding opportunities.
Sam Goldsmith | Senior Commercialisation of Research Manager | Cell and Gene Therapy Catapult
Jenny Laird | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly and Company
Moin Saleem | Professor of Paediatric Renal Medicine | University of Bristol
Raj Mehta | Entrepreneur in Residence | Apple Tree Partners
Kerstin Papenfuss | Associate Director Therapeutics | Deep Science Ventures
Marcelo Bravo | Co Founder & Chief Executive Officer | OXVax
VC judges: what is the X factor?
What are VC Investors looking for at different stages of the life cycle? How is the current economic environment impacting Venture Capital?
Nathan Sigworth | Co-founder and Chief Executive Officer | CCX
Freddie Dear | Head of Corporate Development & Portfolio Manager | Ascend Gene and Cell Therapies
Eric Halioua | President & Chief Executive Officer | PDC*line Pharma
Oliver Sexton | Investment Director | UKI2S
Dominic Schmidt | General Partner | Advent Life Sciences
Chris Baker | Investment Principal | LifeArc Ventures
Karolina Zapadka | Investor | Parkwalk Advisors
Healthy Economics for thriving ATMPs
How do you plan ATMP Health Economics for early-stage R&D, ensuring commercial viability?
Panos Kefalas | Director of the Access Strategy Group | Cell and Gene Therapy Catapult
Simon Chandler | Chief Executive Officer | Rinri Therapeutics
Kirsty Wydenbach | Head of Regulatory Strategy | Weatherden
Paul Catchpole | Value & Access Policy Director | Association of the British Pharmaceutical Industry (ABPI)
Steve Kappenthuler | Chief Business Officer and Co-founder | Muvon Therapeutics
Laura Beswick | Head of Health Economics and Market Access | Cell and Gene Therapy Catapult